Dr William G Collins, PHD | |
300 Sovereign Court, Suite 200, Ballwin, MO 63011 | |
(636) 686-5555 | |
(636) 686-5555 |
Full Name | Dr William G Collins |
---|---|
Gender | Male |
Speciality | Marriage & Family Therapist |
Location | 300 Sovereign Court, Ballwin, Missouri |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1972626711 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | 2001014120 (Missouri) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr William G Collins, PHD 300 Sovereign Court, Suite 200, Ballwin, MO 63011 Ph: (636) 686-5555 | Dr William G Collins, PHD 300 Sovereign Court, Suite 200, Ballwin, MO 63011 Ph: (636) 686-5555 |
News Archive
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
Bayer Inc. announced today that its international trial known as SHARP (Sorafenib HCC Assessment Randomized Protocol), led by Study Manager and Bayer Canada employee Tom Giannaris, has been selected as the winner in the 'Best International Trial' category for the Global Clinical Practice Journal Awards.
A section of the AIDS virus's protein envelope once considered an improbable target for a vaccine now appears to be one of the most promising, new research by Dana-Farber Cancer Institute scientists indicates.
Sierra Sciences, in collaboration with TA Sciences, Geron Corporation, PhysioAge, and the Spanish National Cancer Research Center (CNIO), has announced the first compound ever discovered that activates the enzyme telomerase in the human body - a critical prerequisite for technology that could arrest or reverse the aging process in humans.
Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study.Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president and CEO of Loyola University Health System and chairman of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heat Attack Trial (ALLHAT), which has examined the comparative value of different blood pressure-lowering medications.
› Verified 7 days ago
Melissa Chosid, MSMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 13610 Barrett Office Dr, Suite 108, Ballwin, MO 63021 Phone: 314-441-5509 |